The slow onset of antidepressant drugs' effects is thought to reflect the time required for the development of adaptive changes such as desensitization of presynaptic autoreceptors controlling the release of neurotransmitters. Using in vivo microdialysis in conscious rats, we studied the effect of a continuous infusion of the selective noradrenaline (NA) reuptake inhibitor reboxetine on extracellular concentrations of NA. Doses of 10 mg/kg/day reboxetine through subcutaneous osmotic pumps for 2 days increased extracellular NA by 272% in the dorsal hippocampus (DH) of rats. NA rose significantly more in rats given reboxetine for 7 (469%) and 14 (437%) days. Intraperitoneal injection of 30 mg/kg clonidine, an a 2 -adrenoceptor agonist, reduced the release of NA to 49% of basal levels in rats given vehicle or reboxetine for 2 days, but this effect was markedly less in rats given reboxetine for 7 and 14 days. Likewise, the effect of intrahippocampal infusion of clonidine (0.05 and 0.2 mM) on extracellular NA was significantly attenuated in rats given reboxetine for 7 and 14 days, whereas the injection of 0.6 nmol clonidine into the locus coeruleus caused similar reductions of extracellular NA in the DH and prefrontal cortex (PFC) of rats infused with vehicle (DH À64%; PFC À42%) and reboxetine (DH À45%; PFC À28%) for 14 days. The results indicate that chronic treatment markedly enhances the effect of reboxetine on extracellular NA in the DH and suggest that this effect may be due to the desensitization of hippocampal a 2 -adrenoceptors.
INTRODUCTION
Antidepressant drugs take time to develop their effect, typically 2-3 weeks, regardless of the drug class. This delay, which has driven most recent research into the neurobiological effects of antidepressant drugs, suggests that adaptive changes rather than acute pharmacological effects are responsible for the therapeutic effect. Studies with selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRI) have shown that the increase in endogenous 5-HT in the raphe nuclei, by activating somatodendritic 5-HT 1A autoinhibitory receptors, attenuated their effect in terminal regions (Adell and Artigas, 1991; Artigas et al, 1996; Invernizzi et al, 1992) . Continuous administration of SSRI desensitizes 5-HT 1A autoreceptors. This facilitates their effect on extracellular 5-HT in terminal regions such as the prefrontal cortex (PFC) (Invernizzi et al, 1994) and probably contributes to the slow onset of the therapeutic effect (Blier and de Montigny, 1994) .
Noradrenergic neurons originating in the locus coeruleus (LC), the main source of noradrenaline (NA) neurons in the brain ( Moore and Bloom, 1978) , project diffusely to forebrain regions (Tejani-Butt, 1992) . NA is taken up by the NA transporter found exclusively on the neuronal membrane of noradrenergic cells (Lorang et al, 1994) . Activation of terminal a 2 -adrenoceptors by the endogenous transmitter or exogenous receptor agonists reduces NA release (L'Heureux et al, 1986; Starke, 1977; Westfall, 1977) , whereas blockade of these receptors has the opposite effect (Dennis et al, 1987; Gobert et al, 1997; Mateo et al, 1998; Wortley et al, 1999) . Somatodendritic a 2 -adrenoceptors, by controlling the firing activity of NA neurons of the LC (Cedarbaum and Aghajanian, 1976; Svensson et al, 1975) , contribute to the regulation of action potential-dependent release of NA (Florin-Lechner et al, 1996) .
Microdialysis studies have shown that systemic injection of NA reuptake inhibitors (NRI) raised extracellular NA in the PFC, hippocampus, and LC (Bymaster et al, 2002; Dazzi et al, 2001; L'Heureux et al, 1986; Mateo et al, 1998; Page and Lucki, 2002; Sacchetti et al, 1999 Sacchetti et al, , 2001 ). However, their effect is limited by the concurrent activation of presynaptic a 2 -adrenoceptors. Coadministration of a 2 -adrenoceptor antagonists strongly enhances the NRI-induced rise of extracellular NA in brain regions containing noradrenergic afferents, such as the PFC and hippocampus (Dennis et al, 1987; Mateo et al, 1998; Sacchetti et al, 1999) and in the LC (Mateo et al, 1998) .
We found recently that chronic subcutaneous infusion of reboxetine (10 mg/kg/day for 14 days), a selective NRI (Wong et al, 2000) , through osmotic pumps, enhanced the increase of extracellular NA in the PFC of the rat and reduced the inhibitory effect of intraperitoneal (i.p.) and intracortical clonidine on extracellular NA (Invernizzi et al, 2001) . Similar findings were recently reported by Meana and co-workers, who showed that the reduction of extracellular NA in the cingulate cortex of rats given clonidine systemically or through a cortical probe was markedly attenuated after repeated injections of desipramine (DMI; 6 mg/kg/day) for 2 weeks (Mateo et al, 2001) . Although chronic DMI (10 mg/kg/day for 14 days) attenuated the effect of systemic clonidine on NA release in the dorsal hippocampus (DH), the response of hippocampal a 2 -adrenoceptors was apparently not affected . Furthermore, reduced sensitivity of a 2 -adrenoceptors of the LC during long-term treatment with NRI has been reported in some electrophysiological and biochemical studies (Grandoso et al, 2004; Lacroix et al, 1991; Svensson and Usdin, 1978) but not confirmed by others (Mateo et al, 2001 ; Szabo and Blier, 2001) . Therefore, it is not clear to what extent regional differences in the response to clonidine in rats given chronic NRI reflect intrinsic differences in a 2 -adrenoceptor adaptive processes in the cortex and hippocampus or whether differences in drug and schedule of treatment also play a role.
In view of the clear reduction in a 2 -adrenoceptor sensitivity found in the PFC of rats given chronic reboxetine through osmotic pumps (Invernizzi et al, 2001) , in the present study, we used the same schedule to examine whether similar changes occurred in the DH. We examined the effect of the selective a 2 -adrenoceptor agonist clonidine (Anden et al, 1976) on extracellular NA with the intracerebral microdialysis technique in conscious rats given vehicle or reboxetine for 2, 7 and 14 days. Whenever the response to systemic clonidine differed in rats given chronic vehicle or reboxetine, the drug was infused through the probe or injected into the LC to assess the functional status of terminal and somatodendritic a 2 -adrenoceptors.
MATERIALS AND METHODS

Animals and Drug Treatments
Male rats (CD-COBS, Charles River, Italy) weighing 300730 g (180-200 g at the beginning of chronic experiments), housed under standard laboratory conditions with food and water freely available, were used in all the experiments.
Microdialysis experiments were conducted in conscious, freely moving rats, 24 h after probe implantation. All acute treatments were given once the basal extracellular NA concentrations were stable (two to three consecutive samples not differing by more than 15%). 
Chronic Reboxetine and Effect of Clonidine
Rats were continuously infused with 10 mg/kg/day reboxetine or vehicle (phosphate-buffered saline, PBS) for 2, 7, or 14 days, by osmotic pumps implanted subcutaneously. This dose of reboxetine for 14 days enhanced the increase of extracellular NA and attenuated the inhibitory effect of clonidine on NA release in the PFC (Invernizzi et al, 2001) . The daily dose of reboxetine is referred to the rats' mean body weight, which was 250 g after 1 week of treatment.
A group of rats infused with reboxetine or PBS for 2, 7, or 14 days were implanted with dialysis probes in the DH. The next day, once basal extracellular NA was stable, rats were given two consecutive injections of clonidine (10 and 30 mg/ kg i.p., the second injection 90 min after the first) and extracellular NA was measured for 90 min after each dose.
The sensitivity of somatodendritic and terminal a 2 -autoreceptors in rats given chronic reboxetine was assessed by measuring changes of extracellular NA in response to clonidine injected into the LC or infused through the hippocampal probe.
SURGICAL PROCEDURES
Subcutaneous Osmotic Pumps
Osmotic pumps (Alzet, model 2ML2; Charles River, Calco, Italy) delivering about 5 ml/h for 14 days were used. Rats were anesthetized with 3.5 ml/kg i.p. Equithesin (composition: 1.2 g pentobarbital, 5.3 g chloral hydrate, 2.7 g MgSO 4 heptahydrate, 49.5 ml propylene glycol, 12.5 ml ethanol, and 58 ml distilled water) and the skin was shaved and washed with antiseptic solution. An incision was made between the scapulae and a pocket was created by inserting a hemostat in the incision. The pump was filled with reboxetine dissolved in PBS or vehicle under sterile conditions, inserted into the subcutaneous pocket, and the wound was closed with two clips.
Dialysis Probes
Vertical probes were prepared essentially as described by Robinson and Whishaw (1988) with Cuprophan hollow fibers (Sorin Biomedica, Italy; outer diameter 216 mm). The active surface was 2 mm long for the DH and 4 mm for the PFC. Rats were anesthetized with 3.5 ml/kg i.p. Equithesin and placed on a stereotaxic frame (model 900; David Kopf Instruments, Tujunga, CA, USA). Probes were positioned in the DH and PFC at the following stereotaxic coordinates (in mm): DH, AP À3.8, V 4.5, L 71.9; PFC, AP þ 4.2, L 70.7, V À4.8 from bregma and dura surface (incisor bar À3.3 mm) according to the Paxinos and Watson atlas (1982) . In the DH, the active surface of the probe was in contact with the Chronic reboxetine desensitizes a 2 -adrenoceptor S Parini et al CA1, CA4, and dentate gyrus. The regions of the cortex accessed by the probe included the rostral division of the Cg1, prelimbic, and medial orbital cortex. Representative dialysis sites are shown in Figure 1 . Probes were fixed to the skull with acrylic cement and two stainless-steel screws.
Probe perfusion started about 20 h after probe implantation to allow the collection of at least four samples before the drug challenge. Probes were perfused at 1 ml/min with artificial cerebrospinal fluid (aCSF) containing NaCl 145 mM, KCl 3 mM, CaCl 2 1.26 mM, MgCl 2 1 mM in distilled water, pH 7.4 with 2 mM sodium phosphate buffer, and samples collected every 30 min.
Cannulae Aimed at the LC
Rats were anesthetized and mounted on a stereotaxic apparatus as described above. Guide cannulae (23 gauge, 14 mm long) were implanted 2 mm above the LC ipsilaterally to the cortical or hippocampal probe at the following stereotaxic coordinates (incisor bar À8.9 mm): AP þ 0.9, V À4.1, L 70.9 from interaural line and dura surface according to the Paxinos and Watson atlas (1982) . At the end of surgery, obdurators (30 gauge, 14 mm long) were inserted into the cannulae to prevent clogging. On the next day, once NA release was stable, the obdurators were removed and a needle (30 gauge) protruding 2 mm from the guide was inserted into the LC for the delivery of clonidine or PBS.
HISTOLOGY
At the end of the experiment, rats were deeply anesthetized (400 mg/kg chloral hydrate) and decapitated. The brain was removed and fixed in 4% paraformaldehyde for 3 days and cryoprotected by immersion in 20% sucrose for 2 days. Coronal slices (10 mm) were cut from frozen brain at the level of the DH, PFC, and LC, mounted on polylysinated slices, and stained with cresyl violet.
The correct placement of the dialysis probes and cannulae was verified by histological examination of the tracts (see Figure 1 for an example of probe and cannula placement). Rats with incorrect probe or cannulae placement were not considered in the results.
ANALYTICAL PROCEDURES
NA in the dialysate was measured by high-performance liquid chromatography with electrochemical detection (HPLC-ED). The detector was a Coulochem II (ESA, Chelmsford, MA) equipped with an analytical cell consisting of two in-series electrodes (model 5011, ESA, Chelmsford, MA). The first electrode was set at þ 0.2 V and the second at À0.25 V. NA was read as second electrode output signal.
Separation was obtained using a reverse-phase column (Hypersil-ODS 5 mm, 3.1 Â 125 mm, Bischoff, Italy). The mobile phase consisted of 5.25 g/l citric acid monohydrate, 3.3 g/l sodium acetate trihydrate, 360 mg/l octyl sodium sulfate, 37 mg/l Na 2 EDTA dihydrate, and 80 ml/l methanol pumped at a constant flow of 1 ml/min with an ESA-580 solvent delivery module (ESA, Chelmsford, MA). All chemicals were reagent grade or better from Merck (Bracco, Milan, Italy) or Sigma-Aldrich (Milan, Italy).
DRUGS
Reboxetine methanesulfonate (Pharmacia Corporation, Nerviano, Italy) was dissolved in PBS and infused subcutaneously (10 mg/kg/day) by osmotic pumps. Clonidine HCl (Boehringer Ingelheim, Milano, Italy) was dissolved in PBS and injected i.p. in 2 ml/kg. For intra-LC injections, clonidine HCl (0.2 and 0.6 pmol/0.5 ml) was dissolved in aCSF and injected into the LC through previously implanted guide cannulae. Clonidine or aCSF were delivered at 0.5 ml/min and the needle was left in place for 1 min before withdrawal to allow for diffusion of the drug. All doses are referred to the free base. 
DATA CALCULATION AND STATISTICS
The last of three consecutive stable samples was taken as the basal value of extracellular NA, expressed as fmol/30 ml. Basal values of rats infused with PBS or reboxetine for 2, 7, and 14 days through the osmotic pump were compared by one-way ANOVA followed by Tukey-Kramer's test. The effect of a challenge dose of clonidine in rats given chronic reboxetine or PBS was assessed by ANOVA for repeated measures. When significant effects were found, post hoc comparisons between pre-and postinjection values were made by Dunnett's test.
The overall effect of clonidine challenge in rats given chronic reboxetine or vehicle was assessed by the area under the curve (AUC) calculated for each rat on the percentage of basal values and expressed as % Â min over the interval indicated in the legends to Figures 1-3 . The resulting data were compared by Mann-Whitney's test.
RESULTS
Effect of Chronic Reboxetine on Basal Extracellular NA in the DH
The infusion of 10 mg/kg/day reboxetine for 2 (n ¼ 5), 7 (n ¼ 12), and 14 (n ¼ 21) days through an osmotic pump (still in place during sample collection) significantly increased basal extracellular NA in the DH (F 3,49 ¼ 28.2, po0.0001). As shown in Table 1 , after 7 and 14 days, basal concentrations of NA were increased by, respectively, 469 and 437%. At both times, reboxetine had more effect on extracellular NA in the DH than in rats receiving PBS (n ¼ 15) or reboxetine for 2 days (272%). Extracellular NA concentrations in rats infused with reboxetine for 7 and 14 days were not significantly different. As no significant differences in basal levels of NA were found in rats given PBS for 2 (n ¼ 2), 7 (n ¼ 4), and 14 (n ¼ 9) days, the results were pooled.
Intraperitoneal Clonidine
As shown in Figure 2 , 30 mg/kg clonidine significantly reduced extracellular NA in the DH (F 3,23 ¼ 15.1, po0.0001). The effect was significant in rats given vehicle (49% below basal values), 10 mg/kg/day reboxetine for 2 Chronic reboxetine desensitizes a 2 -adrenoceptor S Parini et al (49%) and 7 days (25%) but not in those infused with the drug for 14 days (17% less than basal values). In all, 10 mg/ kg clonidine (Figure 1 ) or PBS (data not shown) had no significant effect on extracellular NA in any of the experimental groups. The overall effect of 30 mg/kg clonidine on extracellular NA, as estimated by the AUC, was significantly attenuated in rats given reboxetine for 7 and 14 days compared to those receiving PBS or reboxetine for 2 days (po0.05, Mann-Whitney's test).
Intrahippocampal Clonidine
The infusion of clonidine through the probe significantly reduced extracellular NA in the DH of rats given PBS (F 3,6 ¼ 6.6, p ¼ 0.0008) or 10 mg/kg/day reboxetine for 7 (F 5,6 ¼ 3.0, p ¼ 0.02) and 14 days (F 5,6 ¼ 9.4, po0.0001) (Figure 3 ). In rats infused with PBS, extracellular NA reached, respectively, 42 and 28% of basal levels in response to 0.05 and 0.2 mM clonidine. In rats given reboxetine for 7 and 14 days, extracellular NA reached 63 and 76% of basal levels in response to 0.2 mM clonidine and 71 and 83% in those infused with 0.05 mM clonidine. The overall effect of 0.2 mM clonidine on extracellular NA, as evaluated by the AUC, was significantly attenuated by 7 and 14 days at 10 mg/kg/day reboxetine. The effect of 0.05 mM clonidine was also attenuated in the DH of rats given reboxetine for 14 days but not in those given the drug for 7 days. The NA release was stable over the 3-h infusion of normal aCSF (data not shown).
Intra-LC Clonidine
To assess the effect of chronic reboxetine on the sensitivity of somatodendritic a 2 -adrenoceptors regulating the NA release in the DH and PFC, rats were injected with clonidine into the LC. The dose of 0.6 nmol/0.5 ml significantly reduced extracellular NA by, respectively, 64 and 42% in the DH (F 3,12 ¼ 12.4, p ¼ 0.0006) and PFC (F 3,18 ¼ 4.6, p ¼ 0.01) of rats given PBS and by 45% (F 3,9 ¼ 5.0, p ¼ 0.03) and 28% (F 3,12 ¼ 3.9, p ¼ 0.04) in those given 10 mg/kg/day reboxetine for 14 days (Figure 4) . Comparison of AUCs revealed no significant differences in the effect on intra-LC clonidine on NA release in either the DH or PFC of rats given chronic reboxetine or PBS. The injection of aCSF or 0.2 nmol/0.5 ml clonidine into the LC had no significant effect on extracellular NA in the DH and PFC (data not shown).
DISCUSSION
The present study shows that continuous infusion of 10 mg/ kg/day reboxetine through subcutaneous osmotic pumps enhances the drug's ability to raise extracellular NA in the DH and attenuates the inhibitory effect of clonidine on NA release.
Extracellular NA rose more in rats infused with 10 mg/kg/ day reboxetine for 7 and 14 days than in those given the drug for 2 days. This suggests that adaptive changes already occurring after 7 days are likely to be responsible for the drug's enhanced effect. The dose of reboxetine used in the present study maximally increased extracellular NA in the PFC (Invernizzi et al, 2001 ) and its effect on extracellular NA is close to that in the DH (240%) and PFC (242%) of rats given a single high dose (15 mg/kg i.p.) (Sacchetti et al, 1999) . This suggests that under the present experimental conditions, reboxetine maximally inhibits NA reuptake. We have previously shown that brain levels of reboxetine in rats infused with the drug for 2 or 14 days were not significantly different (Invernizzi et al, 2001) . Thus, it can be excluded that more effective blockade of NA reuptake or changes in drug kinetics accounts for the enhancement of reboxetine's effect.
Previous studies have shown that desensitization of somatodendritic 5-HT 1A autoreceptors, developing after chronic blockade of the 5-HT transporter by SSRI, is Chronic reboxetine desensitizes a 2 -adrenoceptor S Parini et al responsible for recovery of the normal firing activity of serotonergic neurons of the dorsal raphe nucleus (Blier and de Montigny, 1994) and the enhanced effect of SSRI on extracellular 5-HT in the PFC (Invernizzi et al, 1994) . We found that the inhibition of hippocampal NA release induced by systemic clonidine was strongly attenuated after 7 and 14 days infusion with reboxetine. Thus, a 2 -adrenoceptors are rapidly desensitized in response to reboxetine and this effect takes about the same time to develop as the enhancement of extracellular NA. This suggests a possible link between desensitization of the a 2 -adrenoceptors inhibiting NA release and enhancement of extracellular NA. Since both terminal and somatodendritic a 2 -adrenoceptors regulate NA release (Mateo et al, 1998) , the attenuation of clonidine's effects in rats given chronic reboxetine may be the expression of adaptive changes in the receptors in the cell bodies of the LC, noradrenergic terminals of the DH or both. We attempted to clarify whether the attenuated effect of clonidine depends on desensitization of terminal or somatodendritic a 2 -adrenoceptors by infusing clonidine through the hippocampal probe or injecting it into the LC. Intrahippocampal infusion markedly reduced extracellular NA in the DH of rats given PBS and this effect was strongly attenuated in rats given reboxetine for 7 and 14 days.
These results suggest that hippocampal a 2 -adrenoceptors become subsensitive during long-term treatment with reboxetine and are consistent with previous findings that hippocampal and cortical a 2 -adrenoceptors are desensitized by chronic reboxetine (10 mg/kg/day for 14 days) and DMI (6-10 mg/kg/day for 14 days) (Invernizzi et al, 2001; Lacroix et al, 1991; Mateo et al, 2001) . However, other studies found no change in the sensitivity of hippocampal a 2 -adrenoceptors after chronic DMI (10-20 mg/kg/day for 21-28 days) (Campbell and McKernan, 1986; Schoffelmeer and Mulder, 1982) . We have already seen that chronic DMI (10 mg/kg/ day for 14 days) did not affect the suppression of NA release by 30 mg/kg clonidine . The reasons for this difference are not clear but may reflect intrinsic differences between reboxetine and DMI or differences in the experimental conditions. One main difference between the present study and that by Sacchetti et al (2001) is the washout period between chronic treatment and clonidine challenge. Whereas in the present study clonidine was injected during reboxetine administration, Sacchetti allowed 48 h washout between the last DMI dose and the injection of clonidine. It could be argued that the activation of autoreceptors by the increased endogenous NA tone might partly prevent clonidine's inhibitory effect on NA release. Thus, the reduced effect of clonidine in rats given chronic reboxetine would not be due to the desensitization of a 2 -adrenoceptors but to occupancy of the autoreceptor by the endogenous agonist.
However, several findings argue against this interpretation. First, the reduction of extracellular NA by clonidine was not affected by a 2-day infusion of reboxetine, a condition in which extracellular NA increases two-to threefold in the DH and five-fold in the LC (see Table 1 ; unpublished results). Corresponding studies with DMI showed that despite a five-fold increase of extracellular NA, acute blockade of NA reuptake had no effect on clonidine-induced inhibition of NA release in the PFC (Mateo et al, 2001) . Second, despite the fact that extracellular NA in the LC increased by more than nine times in response to 14 days reboxetine infusion (unpublished results), injection of clonidine into the LC had the same effect in rats given reboxetine or PBS (present study).
Thus, the development of subsensitivity of a 2 -adrenoceptors regulating NA release appears to be the more parsimonious interpretation of the reduced effect of clonidine in rats given chronic reboxetine. It remains to be established whether in experimental conditions comparable to the present study chronic treatment with DMI will modify the sensitivity of hippocampal a 2 -adrenoceptors.
The present results suggest that desensitization of hippocampal a 2 -adrenoceptors plays a major role in the response to systemic clonidine in rats given chronic reboxetine. This interpretation is supported by the finding that the reduction of hippocampal NA release by intra-LC clonidine was not changed by long-term treatment with reboxetine. The latter finding is fully consistent with the results of microdialysis studies showing that the suppressant effect of intra-LC clonidine on NA release was not modified by long-term treatment with DMI (6 mg/kg/day for 14 days) and the monoamine oxidase (MAO) inhibitor clorgyline (Mateo et al, 2001) . Thus, the firing rate of NA neurons of the LC did not recover and the suppressant effect of clonidine remained unchanged after continuous infusion of reboxetine (2.5 mg/kg/day for 21 days) or repeated doses of MAO inhibitors (Blier and de Montigny, 1985; Blier et al, 1986; Szabo and Blier, 2001 ). This suggests that the sensitivity of somatodendritic a 2 -adrenoceptors of the LC does not change in response to treatments increasing the synaptic availability of NA. However, other studies reported that chronic DMI (6-10 mg/kg/day for 14 days) and imipramine (20 mg/kg/day for 11 days) reduced the response to clonidine or brimoxidine (Grandoso et al, 2004; Lacroix et al, 1991; Svensson and Usdin, 1978) .
The reasons for this discrepancy are not clear, but may reflect differences in experimental conditions, mainly because these studies were carried out 12-36 h after the last injection of the chronic schedule, whereas our study and that of Szabo and Blier (2001) were carried out while reboxetine was still being delivered by the osmotic pump. The scarce selectivity of the NRI used in one study (Svensson and Usdin, 1978) and the possible confounding effect of anesthesia, which depresses the activity of LC neurons and may enhance its inhibition (Valentino and Wehby, 1988) , could have also contributed.
The present findings and previous work by our group (Invernizzi et al, 2001) suggest that desensitization of presynaptic a 2 -adrenoceptors in terminal regions but not those in the LC is involved in the enhancement of extracellular NA by reboxetine. The present study did not address the reasons for the different roles of terminal and somatodendritic a 2 -adrenoceptors. However, one factor that differentiates presynaptic a 2 -adrenoceptors of the DH, PFC and LC might be the large receptor reserve that affects the inhibitory effect of clonidine in the LC (Pineda et al, 1997) , compared to the smaller reserve for clonidine-induced inhibition of NA release from cortical terminals (Agneter et al, 1993) . Thus, desensitization of a large proportion of somatodendritic a 2 -adrenoceptors may leave the effect of clonidine unaltered.
Chronic reboxetine desensitizes a 2 -adrenoceptor S Parini et al
We previously found that repeated daily injections of 15 mg/kg reboxetine for 14 days did not change the rise of extracellular NA induced by reboxetine and the effect of a challenge dose of clonidine on NA release in the DH (Sacchetti et al, 1999) . This was very likely due to the rapid clearance of reboxetine in rats (Dostert et al, 1997) . Stable levels of reboxetine are not achieved with once-daily dosing and this might have prevented the development of adaptive changes in extracellular NA and autoreceptor sensitivity.
Clinical studies using a-methyltyrosine showed that inhibition of catecholamine synthesis rapidly reversed the effect of antidepressant drugs that enhance noradrenergic transmission in depressed patients in remission (Delgado et al, 1993 (Delgado et al, , 2002 Miller et al, 1996) . This highlights the importance of increased brain NA transmission in the therapeutic effect of these antidepressants. Thus, the delayed increase of extracellular NA may be one of the factors in the development of the antidepressant effect of NRI. Blockade of a 2 -adrenoceptors is a faster and more efficient way to enhance the effect of NRI on extracellular NA (see Invernizzi and Garattini, 2004 for a recent review). Thus, coadministration of an NRI with an a 2 -adrenoceptor antagonist such as idazoxan, which may have antidepressant effects by itself (Osman et al, 1989) , should accelerate the antidepressant effect of NRI and might possibly enhance their effect in nonresponsive patients. However, clinical studies addressing this issue are scarce and results are still controversial (Charney et al, 1986; Lauritzen et al, 1992; Schmauss et al, 1988) , so further trials are necessary to assess the validity of this strategy.
In conclusion, we have shown that reboxetine desensitizes a 2 -adrenoceptors controlling NA release. Desensitization of terminal a 2 -adrenoceptors plays a major role in enhancing the effect of reboxetine on extracellular NA and may be one factor contributing to the beneficial effects of antidepressant drugs that inhibit NA reuptake.
